# INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD

> **NCT01016873** · PHASE2 · COMPLETED · sponsor: **Oraya Therapeutics, Inc.** · enrollment: 230 (actual)

## Conditions studied

- AMD
- Wet AMD
- Age-Related Macular Degeneration
- Wet Age-Related Macular Degeneration
- Macular Degeneration
- Eye Diseases
- Retinal Diseases

## Interventions

- **DEVICE:** IRay

## Key facts

- **NCT ID:** NCT01016873
- **Lead sponsor:** Oraya Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2012-05
- **Final completion:** 2014-04
- **Target enrollment:** 230 (ACTUAL)
- **Last updated:** 2014-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01016873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01016873, "INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01016873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*